Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X Syndrome
U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X Syndrome SPG601 is a novel...
Disability
Elucid Names Kelly Huang as CEO
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis softwareBOSTON--(BUSINESS WIRE)--Elucid, a...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had...
Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs...
Med-Metrix Announces the Acquisition of HRSI, Augmenting the Company’s Eligibility Management Capabilities
PARSIPPANY, N.J., July 15, 2024 /PRNewswire/ -- Med-Metrix, LLC ("Med-Metrix", or the "Company"), a leading provider of technology-enabled, Revenue Cycle...
Guidehouse and HIMSS Partner with the Missouri DHSS on Digital Health Assessment
First of its Kind Initiative to Guide Future Improvements in Data Collection, Management, and Utilization to Enhance Efficiencies and Improve...
R.O.S.A. from Trusaic Optimizes Pay Equity Remediation Efforts
Game-changing PayParity® tool optimizes salary adjustments tomaximize ROI and impact on employees LOS ANGELES, July 10, 2024 /PRNewswire/ -- Trusaic's...
Cresilon’s Revolutionary Hemostatic Gel Technology Shows Promising Results for Treatment of Penetrating Traumatic Brain Injury in Study Performed with Walter Reed Army Institute of Research
Findings from preclinical study demonstrate potential for a field and prehospital treatment following a penetrating TBI NEW YORK, July 9,...
Leading Medical Claims Management provider, Medlogix, LLC Announces the Acquisition of ReviewWorks
HAMILTON, N.J., July 8, 2024 /PRNewswire/ -- Medlogix, LLC, a leading, national medical claims management solutions provider, announced today that...
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than...
South Dakota Partners with Trualta to Support Family Caregivers
All caregivers in the state can access free resources at home PIERRE, S.D., June 27, 2024 /PRNewswire/ --The South Dakota...
Neuro20 Sparks Hope for Long COVID Recovery
White Paper discussing patient improvements and potential mechanisms for patients with Long COVID.TAMPA, FL / ACCESSWIRE / June 27, 2024...
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
The device is intended for initial treatment in the acute settingSARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc....
Lifeward Unveils Newest Addition to Its AlterG Anti-Gravity Product Line – Introducing AlterG NEO
Elevate your practice and revolutionize patient care with the all-new user-friendly design and the same patented DAP technology for precise...
Linus Health Introduces Person-Centered Approach to Establish Clinically Meaningful Benefits and Personalized Brain Health Care
Scalable, systematic and automated process captures and monitors metrics based on patients' treatment priorities for managing Alzheimer's disease and related dementias...
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
New molecule demonstrates efficacy in a challenging SCI modelExpanding pipeline into new indications of ischemic stroke and ALSVancouver, British Columbia--(Newsfile...
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who...
Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV)...